Aptose Biosciences Inc.
Datakwaliteit: 83%
APTOF
OTC
Manufacturing
Chemicals
€ 1,71
▲
€ 0,03
(1,79%)
Marktkapitalisatie: 4,41 M
Prijs
€ 1,71
Marktkapitalisatie
4,41 M
Dagbereik
€ 1,71 — € 1,73
52-Weeksbereik
€ 0,64 — € 2,50
Volume
186
Openen € 1,71
50D / 200D Gem.
€ 1,63
4,83% above
50D / 200D Gem.
€ 1,43
19,76% above
Quick Summary
Belangrijkste Punten
Negative free cash flow of -21,99 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,53
Interest CoverageN/A
Waardering
PE (TTM)
-0,17
Boven sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,2 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -25,47 M |
| ROE | N/A | ROA | -426,89% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -21,99 M |
| ROIC | N/A | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,53 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | -3,30 M | Tangible Book Value | -19,45 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,17 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -498,66% | ||
| Market Cap | 4,41 M | Enterprise Value | 3,80 M |
| Per Share | |||
| EPS (Diluted TTM) | -10,41 | Revenue / Share | N/A |
| FCF / Share | -8,53 | OCF / Share | -8,53 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 86,34% |
| SBC-Adj. FCF | -22,41 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -25,47 M | -25,43 M | -51,21 M | -41,82 M | -65,35 M |
| EPS (Diluted) | -10,41 | -36,38 | -7,58 | -0,45 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 11,34 M | 15,10 M | 33,27 M | 28,09 M | 45,99 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | 88.000,0 | 120.000,0 | 150.000,0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | 0,0 | 0,0 | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 10,01 M | 10,13 M | 12,99 M | 51,03 M | 82,53 M |
| Total Liabilities | 37,18 M | 14,67 M | 15,89 M | 13,29 M | 8,29 M |
| Shareholders' Equity | -27,17 M | -4,54 M | -2,90 M | 37,74 M | 74,24 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 935.000,0 | 6,15 M | 9,25 M | 36,97 M | 39,11 M |
| Current Assets | 6,45 M | 9,53 M | 11,89 M | 49,52 M | 81,74 M |
| Current Liabilities | 9,31 M | 4,46 M | 15,27 M | 12,28 M | 8,17 M |
{"event":"ticker_viewed","properties":{"ticker":"APTOF","listing_kind":"stock","pathname":"/stocks/aptof","exchange":"OTC","country":"US"}}